PL EN


Preferences help
enabled [disable] Abstract
Number of results
2002 | 49 | 1 | 121-128
Article title

TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine.

Content
Title variants
Languages of publication
EN
Abstracts
EN
The TEL/JAK2 chromosomal translocation (t(9;12)(p24;p13)) is associated with T cell childhood acute lymphoblastic leukemia. The TEL/JAK2 fusion protein contains the JAK2 catalytic domain and the TEL-specific oligomerization domain. TEL-mediated oligomerization of the TEL/JAK2 proteins results in the constitutive activation of the tyrosine kinase activity. Leukemia cells expressing TEL/JAK2 tyrosine kinase become resistant to anti-neoplastic drugs. Amifostine is a pro-drug which can selectively protect normal tissues against the toxicity of anticancer drugs and radiation. investigated the effects of amifostine on idarubicin-induced DNA damage and repair in murine pro-B lymphoid BaF3 cells and BaF3-TEL/JAK2-transformed cells using alkaline single cell gel electrophoresis (comet assay). Idarubicin induced DNA damage in both cell types but amifostine reduced its extent in control non-transformed BaF3 cells and enhanced it in TEL/JAK2-transformed cells. The transformed cells did not show measurable DNA repair after exposure to amifostine and idarubicin, but cells treated only with idarubicin were able to recover within a 60-min incubation. Because TEL/JAK2-transformed cells can be considered as model cells for certain human leukemias and lymphomas we anticipate an enhancement of idarubicin cytotoxicity by amifostine in these diseases. Moreover, TEL/JAK2 tyrosine kinase might be involved in cellular response to DNA damage. Amifostine could promote apoptosis or lower the threshold for apoptosis induction dependent on TEL/JAK2 activation.
Year
Volume
49
Issue
1
Pages
121-128
Physical description
Dates
published
2002
received
2001-09-10
revised
2002-01-03
accepted
2002-02-21
Contributors
author
  • Department of Molecular Genetics, University of Łódź, S. Banacha 12/16, 90-237 Łódź, Poland
  • Department of Molecular Genetics, University of Łódź, Łódź, Poland
  • Oncohaematology Unit, Clinic of Pediatrics, Institute of Pediatrics, Medical University of Łódź, Łódź, Poland
  • Oncohaematology Unit, Clinic of Pediatrics, Institute of Pediatrics, Medical University of Łódź, Łódź, Poland
  • Medical Center for Postgraduate Education, Warszawa, Poland
  • Center for Biotechnology, College of Science and Technology, Temple University, 1900 N. 12th Street, Philadelphia, PA 19122, U.S.A.
  • Department of Molecular Genetics, University of Łódź, S. Banacha 12/16, 90-237 Łódź, Poland
References
  • 1. Rabbitts, T.H. (1994) Chromosomal translocations in human cancer. Nature 372, 143-149.
  • 2. Peeters, P., Raynaud, S.D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den Berghe, H. & Marynen, P. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of the t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90, 2535-2540.
  • 3. Sawyers, C.L. (1999) Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340.
  • 4. Ihle, J.N. (1996) Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. Adv Cancer Res. 68, 23-65.
  • 5. Bernard, O.A., Romana, S.P., Poirel, H. & Berger, R. (1996) Molecular cytogenetics of t(12;21) (p13;q22). Leuk. Lymphoma 23, 459-456.
  • 6. Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., Asano, S. & Kamada, N. (1999) Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13; q25). Blood 93, 1355-1363.
  • 7. Schwaller, J., Frantsve, J., Aster, J., Williams, I.R., Tomasson, M.H., Ross, T.S., Peeters, P., Van Rompaey, L., Van Etten, R.A., Ilaria, R., Jr., Marynen, P. & Gilliland, D.G. (1998) Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17, 5321-5333.
  • 8. Lacronique, V., Boureux, A., Monni, R., Dumon, S., Mauchauffe, M., Mayeux, P., Gouilleux, F., Berger, R., Gisselbrecht, S., Ghysdael, J. & Bernard, O.A. (2000) Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95, 2076-2083.
  • 9. Ho, J.M., Beattie, B.K., Squire, J.A., Frank, D.A. & Barber, D.L. (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 93, 4354-4364.
  • 10. Nguyen, M.H., Ho, J.M., Beattie, B.K. & Barber, D.L. (2001) TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3' -kinase/protein kinase B signaling pathway. J. Biol. Chem. 276, 32704-32713.
  • 11. Frantsve, J., Schwaller, J., Sternberg, D.W., Kutok, J. & Gilliland, D.G. (2001) Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol. Cell. Biol. 21, 3547-3557.
  • 12. Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Fishel, R., Blasiak, J. & Skorski, T.(2002) Fusion tyrosine kinases induce therapeutic drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase and protection from apoptosis. Mol. Cell. Biol. 22, 4189-201.
  • 13. Schneider, E., Hsiang, Y. & Liu, L.F. (1990) DNA topoisomerases as anticancer drug targets. Adv. Pharmacol. 21, 149-183.
  • 14. Platel, D., Pouna, P., Bonoron-Adele, D. & Robert, J. (1999) Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. Anticancer Drugs 10, 671-676.
  • 15. Mitchell, J.L.A., Judd, G.G., Diveley, R.R., Choe, C.Y. & Leyser, A. (1995) Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278. Carcinogenesis 16, 3063-3068.
  • 16. Milligan, J.R., Aguilera, J.A., Wu, C.C., Paglinawan, R.A., Nguyen, T.T., Wu, D. & Ward, J.F. (1997) Effect of hydroxyl radical scavenging capacity on clustering of DNA damage. Radiat. Res. 148, 325-329.
  • 17. Ramakrishnan, N. & Catravas, G.N. (1992) N-(2-mercaptoethyl)-1,3-propanediamine (WR- 1065) protects thymocytes from programmed cell death. J. Immunol. 148, 1817-1821.
  • 18. Liu, S.C., Murley, J.S., Woloschak, G. & Grdina, D.J. (1997) Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis 18, 2457-2459.
  • 19. Murley, J.S., Constantinou, A., Kamath, N.S. & Grdina, D.J. (1997) WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Proliferation 30, 283-294.
  • 20. Douay, L., Hu, C., Giarratana, M.C., Bouchet, S., Conlon, J., Capizzi, R.L. & Gorin, N.C. (1995) Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging. Blood 86, 2849-2855.
  • 21. Valeriote, F. & Tolen, S. (1982) Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 42, 4330-4331.
  • 22. Huang, X.K., Gao, X.Z., Burke, P., Raza, A. & Preisler, H.D. (1997) The effects of amifostine on the clonogenic proliferation in vitro of myelodysplastic and acute and chronic myelogenous leukemia cells. ASCO Proc. 16, 1848a.
  • 23. Singh, N.P., McCoy, T., Tice, R.R. & Schneider, E.L. (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175, 184-192.
  • 24. Klaude, M., Eriksson, S., Nygren, J. & Ahnstrom, G. (1996) The comet assay: Mechanisms and technical considerations. Mutat. Res. 363, 89-96.
  • 25. Błasiak, J. & Kowalik, J. (2001) Protective action of vitamin C against DNA damage induced by selenium-cisplatin conjugate. Acta Biochim. Polon. 48, 233-240.
  • 26. Ashby, J.A., Tinwell, H., Lefevre, P.A. & Brown, M.A. (1995) The single cell gel electrophoresis assay for induced DNA damage (comet assay): Measurement of tail lenght and moment. Mutagenesis 10, 85-90.
  • 27. Kurbacher, C.M. & Mallmann, P.K. (1998) Chemoprotection in anticancer therapy: The emerging role of amifostine (WR-2721). Anticancer Res. 18, 2203-2210.
  • 28. Pierelli, L., Scambia, G., Fattorossi, A., Bonanno, G., Battaglia, A., Perillo, A., Menichella, G., Panici, P.B., Leone, G. & Mancuso, S. (1998) In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: Haematoprotection acts as a drug-specific progenitor rescue. Br. J. Cancer 78, 1024-1029.
  • 29. Buschini, A., Anceschi, E., Carlo-Stella, C., Regazzi, E., Rizzoli, V., Poli, P. & Rossi, C. (2000) Amifostine (WR2721) selective protection against melphalan genotoxicity. Leukemia 14, 1642-1651.
  • 30. Newton, G.L., Aguilera, J.A., Ward, J.F. & Fahey, R.C. (1996) Binding of radioprotective thiols and disulfides in Chinese hamster V79 cell nuclei. Radiat. Res. 146, 298-305.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv49i1p121kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.